You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 25, 2024

VERELAN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Verelan patents expire, and when can generic versions of Verelan launch?

Verelan is a drug marketed by Azurity and is included in two NDAs.

The generic ingredient in VERELAN is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Verelan

A generic version of VERELAN was approved as verapamil hydrochloride by EXELA PHARMA on March 30th, 1984.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for VERELAN?
  • What are the global sales for VERELAN?
  • What is Average Wholesale Price for VERELAN?
Summary for VERELAN
Drug patent expirations by year for VERELAN
Drug Prices for VERELAN

See drug prices for VERELAN

Recent Clinical Trials for VERELAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Assiut UniversityEarly Phase 1
TheracosPhase 1
City of Hope Medical CenterPhase 1

See all VERELAN clinical trials

US Patents and Regulatory Information for VERELAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Azurity VERELAN verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019614-001 May 29, 1990 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Azurity VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-003 Nov 25, 1998 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Azurity VERELAN verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019614-004 May 10, 1996 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Azurity VERELAN verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019614-003 Jan 9, 1992 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Azurity VERELAN verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019614-002 May 29, 1990 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Azurity VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-002 Nov 25, 1998 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Azurity VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-001 Nov 25, 1998 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VERELAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Azurity VERELAN verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019614-001 May 29, 1990 ⤷  Sign Up ⤷  Sign Up
Azurity VERELAN verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019614-004 May 10, 1996 ⤷  Sign Up ⤷  Sign Up
Azurity VERELAN verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019614-002 May 29, 1990 ⤷  Sign Up ⤷  Sign Up
Azurity VERELAN verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019614-003 Jan 9, 1992 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for VERELAN

See the table below for patents covering VERELAN around the world.

Country Patent Number Title Estimated Expiration
Australia 599385 ⤷  Sign Up
Australia 7452887 ⤷  Sign Up
Ireland 58401 Controlled absorption pharmaceutical composition ⤷  Sign Up
Japan 2637981 ⤷  Sign Up
Spain 2039440 ⤷  Sign Up
Austria 72975 ⤷  Sign Up
Germany 3776982 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.